ZNF286B

Across TCGA pan-cancer cohorts, ZNF286B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF286B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF286B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF286B expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, UCS, and SARC are the cancer types where ZNF286B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.891	0.430	.012	22	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
SARC	DFS	Median	All	0.006	0.611	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.091	0.553	.013	6	view →
BLCA	DFS	Median	All	1.000	0.330	.045	4	view →
LUAD	OS	Median	II,III,IV	0.469	0.711	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF286B–UCEC (DFS)

Open the UCEC breakdown →